Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors

Improved bioavailability enhances anticonvulsant efficacy

J. M. Witkin, Jodi Smith, X. Ping, S. D. Gleason, M. M. Poe, G. Li, Xiaoming Jin, J. Hobbs, J. M. Schkeryantz, J. S. McDermott, A. I. Alatorre, J. N. Siemian, J. W. Cramer, D. C. Airey, K. R. Methuku, V. V.N.P.B. Tiruveedhula, T. M. Jones, J. Crawford, M. J. Krambis, J. L. Fisher & 2 others J. M. Cook, R. Cerne

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

HZ-166 has previously been characterized as an α2,3-selective GABAA receptor modulator with anticonvulsant, anxiolytic, and anti-nociceptive properties but reduced motor effects. We discovered a series of ester bioisosteres with reduced metabolic liabilities, leading to improved efficacy as anxiolytic-like compounds in rats. In the present study, we evaluated the anticonvulsant effects KRM-II-81 across several rodent models. In some models we also evaluated key structural analogs. KRM-II-81 suppressed hyper-excitation in a network of cultured cortical neurons without affecting the basal neuronal activity. KRM-II-81 was active against electroshock-induced convulsions in mice, pentylenetetrazole (PTZ)-induced convulsions in rats, elevations in PTZ-seizure thresholds, and amygdala-kindled seizures in rats with efficacies greater than that of diazepam. KRM-II-81 was also active in the 6 Hz seizure model in mice. Structural analogs of KRM-II-81 but not the ester, HZ-166, were active in all models in which they were evaluated. We further evaluated KRM-II-81 in human cortical epileptic tissue where it was found to significantly-attenuate picrotoxin- and AP-4-induced increases in firing rate across an electrode array. These molecules generally had a wider margin of separation in potencies to produce anticonvulsant effects vs. motor impairment on an inverted screen test than did diazepam. Ester bioisosters of HZ-166 are thus presented as novel agents for the potential treatment of epilepsy acting via selective positive allosteric amplification of GABAA signaling through α2/α3-containing GABA receptors. The in vivo data from the present study can serve as a guide to dosing parameters that predict engagement of central GABAA receptors.

Original languageEnglish (US)
Pages (from-to)332-343
Number of pages12
JournalNeuropharmacology
Volume137
DOIs
StatePublished - Jul 15 2018

Fingerprint

GABA-A Receptors
Anticonvulsants
Biological Availability
Seizures
Pentylenetetrazole
Esters
Anti-Anxiety Agents
Diazepam
Picrotoxin
Electroshock
GABA Receptors
Amygdala
Rodentia
Epilepsy
Electrodes
8-ethynyl-6-(2'-pyridine)-4H-2,5,10b-triazabenzo(e)azulene-3-carboxylic acid ethyl ester
Neurons

Keywords

  • Alpha 2/3 subunit
  • Anxiety
  • Epilepsy
  • GABA-A receptors

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors : Improved bioavailability enhances anticonvulsant efficacy. / Witkin, J. M.; Smith, Jodi; Ping, X.; Gleason, S. D.; Poe, M. M.; Li, G.; Jin, Xiaoming; Hobbs, J.; Schkeryantz, J. M.; McDermott, J. S.; Alatorre, A. I.; Siemian, J. N.; Cramer, J. W.; Airey, D. C.; Methuku, K. R.; Tiruveedhula, V. V.N.P.B.; Jones, T. M.; Crawford, J.; Krambis, M. J.; Fisher, J. L.; Cook, J. M.; Cerne, R.

In: Neuropharmacology, Vol. 137, 15.07.2018, p. 332-343.

Research output: Contribution to journalArticle

Witkin, JM, Smith, J, Ping, X, Gleason, SD, Poe, MM, Li, G, Jin, X, Hobbs, J, Schkeryantz, JM, McDermott, JS, Alatorre, AI, Siemian, JN, Cramer, JW, Airey, DC, Methuku, KR, Tiruveedhula, VVNPB, Jones, TM, Crawford, J, Krambis, MJ, Fisher, JL, Cook, JM & Cerne, R 2018, 'Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: Improved bioavailability enhances anticonvulsant efficacy', Neuropharmacology, vol. 137, pp. 332-343. https://doi.org/10.1016/j.neuropharm.2018.05.006
Witkin, J. M. ; Smith, Jodi ; Ping, X. ; Gleason, S. D. ; Poe, M. M. ; Li, G. ; Jin, Xiaoming ; Hobbs, J. ; Schkeryantz, J. M. ; McDermott, J. S. ; Alatorre, A. I. ; Siemian, J. N. ; Cramer, J. W. ; Airey, D. C. ; Methuku, K. R. ; Tiruveedhula, V. V.N.P.B. ; Jones, T. M. ; Crawford, J. ; Krambis, M. J. ; Fisher, J. L. ; Cook, J. M. ; Cerne, R. / Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors : Improved bioavailability enhances anticonvulsant efficacy. In: Neuropharmacology. 2018 ; Vol. 137. pp. 332-343.
@article{ef93d7ada10247e98049d77aa5384c61,
title = "Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: Improved bioavailability enhances anticonvulsant efficacy",
abstract = "HZ-166 has previously been characterized as an α2,3-selective GABAA receptor modulator with anticonvulsant, anxiolytic, and anti-nociceptive properties but reduced motor effects. We discovered a series of ester bioisosteres with reduced metabolic liabilities, leading to improved efficacy as anxiolytic-like compounds in rats. In the present study, we evaluated the anticonvulsant effects KRM-II-81 across several rodent models. In some models we also evaluated key structural analogs. KRM-II-81 suppressed hyper-excitation in a network of cultured cortical neurons without affecting the basal neuronal activity. KRM-II-81 was active against electroshock-induced convulsions in mice, pentylenetetrazole (PTZ)-induced convulsions in rats, elevations in PTZ-seizure thresholds, and amygdala-kindled seizures in rats with efficacies greater than that of diazepam. KRM-II-81 was also active in the 6 Hz seizure model in mice. Structural analogs of KRM-II-81 but not the ester, HZ-166, were active in all models in which they were evaluated. We further evaluated KRM-II-81 in human cortical epileptic tissue where it was found to significantly-attenuate picrotoxin- and AP-4-induced increases in firing rate across an electrode array. These molecules generally had a wider margin of separation in potencies to produce anticonvulsant effects vs. motor impairment on an inverted screen test than did diazepam. Ester bioisosters of HZ-166 are thus presented as novel agents for the potential treatment of epilepsy acting via selective positive allosteric amplification of GABAA signaling through α2/α3-containing GABA receptors. The in vivo data from the present study can serve as a guide to dosing parameters that predict engagement of central GABAA receptors.",
keywords = "Alpha 2/3 subunit, Anxiety, Epilepsy, GABA-A receptors",
author = "Witkin, {J. M.} and Jodi Smith and X. Ping and Gleason, {S. D.} and Poe, {M. M.} and G. Li and Xiaoming Jin and J. Hobbs and Schkeryantz, {J. M.} and McDermott, {J. S.} and Alatorre, {A. I.} and Siemian, {J. N.} and Cramer, {J. W.} and Airey, {D. C.} and Methuku, {K. R.} and Tiruveedhula, {V. V.N.P.B.} and Jones, {T. M.} and J. Crawford and Krambis, {M. J.} and Fisher, {J. L.} and Cook, {J. M.} and R. Cerne",
year = "2018",
month = "7",
day = "15",
doi = "10.1016/j.neuropharm.2018.05.006",
language = "English (US)",
volume = "137",
pages = "332--343",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors

T2 - Improved bioavailability enhances anticonvulsant efficacy

AU - Witkin, J. M.

AU - Smith, Jodi

AU - Ping, X.

AU - Gleason, S. D.

AU - Poe, M. M.

AU - Li, G.

AU - Jin, Xiaoming

AU - Hobbs, J.

AU - Schkeryantz, J. M.

AU - McDermott, J. S.

AU - Alatorre, A. I.

AU - Siemian, J. N.

AU - Cramer, J. W.

AU - Airey, D. C.

AU - Methuku, K. R.

AU - Tiruveedhula, V. V.N.P.B.

AU - Jones, T. M.

AU - Crawford, J.

AU - Krambis, M. J.

AU - Fisher, J. L.

AU - Cook, J. M.

AU - Cerne, R.

PY - 2018/7/15

Y1 - 2018/7/15

N2 - HZ-166 has previously been characterized as an α2,3-selective GABAA receptor modulator with anticonvulsant, anxiolytic, and anti-nociceptive properties but reduced motor effects. We discovered a series of ester bioisosteres with reduced metabolic liabilities, leading to improved efficacy as anxiolytic-like compounds in rats. In the present study, we evaluated the anticonvulsant effects KRM-II-81 across several rodent models. In some models we also evaluated key structural analogs. KRM-II-81 suppressed hyper-excitation in a network of cultured cortical neurons without affecting the basal neuronal activity. KRM-II-81 was active against electroshock-induced convulsions in mice, pentylenetetrazole (PTZ)-induced convulsions in rats, elevations in PTZ-seizure thresholds, and amygdala-kindled seizures in rats with efficacies greater than that of diazepam. KRM-II-81 was also active in the 6 Hz seizure model in mice. Structural analogs of KRM-II-81 but not the ester, HZ-166, were active in all models in which they were evaluated. We further evaluated KRM-II-81 in human cortical epileptic tissue where it was found to significantly-attenuate picrotoxin- and AP-4-induced increases in firing rate across an electrode array. These molecules generally had a wider margin of separation in potencies to produce anticonvulsant effects vs. motor impairment on an inverted screen test than did diazepam. Ester bioisosters of HZ-166 are thus presented as novel agents for the potential treatment of epilepsy acting via selective positive allosteric amplification of GABAA signaling through α2/α3-containing GABA receptors. The in vivo data from the present study can serve as a guide to dosing parameters that predict engagement of central GABAA receptors.

AB - HZ-166 has previously been characterized as an α2,3-selective GABAA receptor modulator with anticonvulsant, anxiolytic, and anti-nociceptive properties but reduced motor effects. We discovered a series of ester bioisosteres with reduced metabolic liabilities, leading to improved efficacy as anxiolytic-like compounds in rats. In the present study, we evaluated the anticonvulsant effects KRM-II-81 across several rodent models. In some models we also evaluated key structural analogs. KRM-II-81 suppressed hyper-excitation in a network of cultured cortical neurons without affecting the basal neuronal activity. KRM-II-81 was active against electroshock-induced convulsions in mice, pentylenetetrazole (PTZ)-induced convulsions in rats, elevations in PTZ-seizure thresholds, and amygdala-kindled seizures in rats with efficacies greater than that of diazepam. KRM-II-81 was also active in the 6 Hz seizure model in mice. Structural analogs of KRM-II-81 but not the ester, HZ-166, were active in all models in which they were evaluated. We further evaluated KRM-II-81 in human cortical epileptic tissue where it was found to significantly-attenuate picrotoxin- and AP-4-induced increases in firing rate across an electrode array. These molecules generally had a wider margin of separation in potencies to produce anticonvulsant effects vs. motor impairment on an inverted screen test than did diazepam. Ester bioisosters of HZ-166 are thus presented as novel agents for the potential treatment of epilepsy acting via selective positive allosteric amplification of GABAA signaling through α2/α3-containing GABA receptors. The in vivo data from the present study can serve as a guide to dosing parameters that predict engagement of central GABAA receptors.

KW - Alpha 2/3 subunit

KW - Anxiety

KW - Epilepsy

KW - GABA-A receptors

UR - http://www.scopus.com/inward/record.url?scp=85046681321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046681321&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2018.05.006

DO - 10.1016/j.neuropharm.2018.05.006

M3 - Article

VL - 137

SP - 332

EP - 343

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -